The company will report its revenue for FY 2016 on 01/27/2017. Generally, the company reports sales worse than estimates. In recent months, the 4 analysts from Thomson Reuters consensus have revised their sales estimates downward.
Annual sales is expected at 16.75 M EUR for 2016 (+ 28289.8% from 2015). A summary of annual publications and estimates is available below.
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
POXEL 
